- Ongoing, recruitingTherapeutic exploratory (Phase II)
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
This study looks at ways to prevent infusion reactions in people with advanced lung cancer receiving a new combination of medicines. Researchers are testing different medications given before treatment to see if they can reduce side effects when the main cancer drug is given through a drip.
For: EGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerFrance · Spain - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib (JNJ-73841937)
This study is looking at how a new drug, Lazertinib, is absorbed by the body. It’s for healthy adults and compares two different tablet versions of the drug to see if they work the same way. This helps make sure future patients get the best possible treatment.
For: Non-small cell lung cancer (NSCLC)Belgium